[1] Robakis NK, Devine-Gage EA, Jenkins EC, et al. Localization of a human gene homologous to the PrP gene on the p ARM of chromosome 20 and detection of PrP-related antigens in normal human brain. Biochem Biophys Res Commun, 1986; 140, 758−65. doi:  10.1016/0006-291X(86)90796-5
[2] Brown P, Cervenáková L, Goldfarb LG, et al. Iatrogenic Creutzfeldt-Jakob disease: an example of the interplay between ancient genes and modern medicine. Neurol, 1994; 44, 291−3. doi:  10.1212/WNL.44.2.291
[3] Dormont D. Prion diseases: pathogenesis and public health concerns. Febs Letters, 2002; 529, 17−21. doi:  10.1016/S0014-5793(02)03268-4
[4] Isabelle LP, Caroline F, Luc R, et al. Developmental changes in cellular prion protein in primate visual cortex. J Comp Neurol, 2010; 504, 646−58.
[5] Yasuro A, Naotaka I. Distribution of the cellular prion protein in the central nervous system of the chicken. J Chem Neuroanat, 2009; 38, 292−301. doi:  10.1016/j.jchemneu.2009.09.001
[6] Gill AC, Castle AR. The cellular and pathologic prion protein. Handbook of clinical neurology, 2018; 153.
[7] Krasemann S, Jürgens T, Bodemer W. Generation of monoclonal antibodies against prion proteins with an unconventional nucleic acid-based immunization strategy. J Biotechnol, 1999; 73, 119−29. doi:  10.1016/S0168-1656(99)00115-7
[8] Ostapchenko VG, Makarava N, Savtchenko R, et al. The polybasic N-terminal region of the prion protein controls the physical properties of both the cellular and fibrillar forms of PrP. J Mol Biol, 2008; 383, 1210−24. doi:  10.1016/j.jmb.2008.08.073
[9] Büeler H, Fischer M, Lang Y, et al. Normal development and behaviour of mice lacking the neuronal cell-surface PrP protein. Nature, 1992; 356, 577−82. doi:  10.1038/356577a0
[10] Goldman JS. Prion disease. Genetic counseling for adult neurogenetic disease, 2015; 121−9.
[11] Yue M, Gao L, Kang X, et al. Alteration of NF-κB(p65) in brain tissue of scrapie-139A infected mice. Dis Surveill, 2018; 33, 32−6.
[12] Sadowski MJ, Pankiewicz J, Prelli F, et al. Anti-PrP Mab 6D11 suppresses PrP replication in prion infected myeloid precursor line FDC-P1/22L and in the lymphoreticular system in vivo. Neurobiol Dis, 2009; 34, 267−78. doi:  10.1016/j.nbd.2009.01.013
[13] Takeshi Y, Akio S, Rie H, et al. Comparison of the anti-prion mechanism of four different anti-prion compounds, anti-PrP monoclonal antibody 44B1, pentosan polysulfate, chlorpromazine, and U18666A, in prion-infected mouse neuroblastoma cells. PLoS One, 2014; 9, e106516. doi:  10.1371/journal.pone.0106516
[14] Zhao X, Dong X, Zhou W. Preparation of polyclonal antibody to human prion protein using the expressed GST-PrP fusion protein as antigen. Chin J Experi Clin Virol, 2000; 14, 131−3.
[15] Lu Y, Li ZW, Yang LF, et al. The overview of methods for detecting prion disease. China Animal Husbandry & Veterinary Medicine, 2011; 38, 166−9.
[16] Wadsworth J DF, Adamson G, Joiner S, et al. Methods for molecular diagnosis of human Prion Dis. Methods Mol Biol, 2017; 311−46.
[17] Hasegawa K, Mohri S, Yokoyama T. Comparison of the local structural stabilities of mammalian prion protein (PrP) by fragment molecular orbital calculations. Prion, 2013; 7, 185−91. doi:  10.4161/pri.23122
[18] Scheckel C, Aguzzi A. Prions, prionoids and protein misfolding disorders. Nature Rev Gene, 2018; 19, 405−18. doi:  10.1038/s41576-018-0011-4